㈜셀레믹스

Publications

Celemics’ Publications

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells

  • Post category:Oncology

Exp Cell Res

The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells

Lee T-G, Kang H-M, Kim SY, Kim H-R, Kim CH. The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells. Exp Cell Res. 2023;430(1):113722.

 

10.1016/j.yexcr.2023.113722